Related Experiment Video
Updated: Sep 30, 2025

Author Spotlight: Assessing the Cardiovascular Profile of Patients with Metabolic Syndrome
Published on: September 27, 2024
How should public health recommendations address Lp(a) measurement, a causative risk factor for cardiovascular
Alberico L Catapano1, Magdalena Daccord2, Elaine Damato3
1Director Center for the Study of Atherosclerosis at Bassini Hospital University of Milan, Milan, Italy.
Insights
Wider measurement of Lipoprotein (a) [Lp(a)], a key inherited risk factor for atherosclerotic cardiovascular disease (ASCVD), offers significant clinical and economic benefits today. Addressing barriers to Lp(a) testing is crucial for realizing these advantages.
Area of Science:
- Cardiology
- Clinical Chemistry
- Health Economics
Background:
- Elevated Lipoprotein (a) [Lp(a)] is an inherited, causal risk factor for atherosclerotic cardiovascular disease (ASCVD).
- Understanding the clinical utility and economic impact of widespread Lp(a) measurement is essential for cardiovascular disease (CVD) management.
- Current guidelines and awareness may limit the broader adoption of Lp(a) testing.
Purpose of the Study:
- To investigate the clinical utility of measuring Lipoprotein (a) [Lp(a)] concentrations for patients.
- To evaluate the economic benefits to healthcare systems and society of wider Lp(a) measurement.
- To identify barriers to Lp(a) measurement uptake and propose solutions.
Main Methods:
- A structured literature review was conducted to identify economic and health benefits and costs associated with Lp(a) measurement.
- Potential barriers to Lp(a) testing uptake and solutions were identified.
- Findings were discussed in an advisory board with experts and patient organizations.
Main Results:
- Wider measurement of Lp(a) concentration provides clinical and economic benefits to patients, healthcare systems, and society, even before specific Lp(a)-lowering treatments are available.
- Increased Lp(a) measurement uptake can support the development of crucial epidemiological data.
- The study identified key barriers including perceived limited clinical value, lack of awareness, insufficient data on CV benefit, and technical/guideline/healthcare system issues.
Conclusions:
- Addressing barriers such as perceived limited clinical value and lack of awareness is vital for increasing Lp(a) measurement uptake.
- Collaboration between scientific communities and industry is needed to overcome technical and guideline challenges.
- Policy interventions are crucial for national atherosclerotic cardiovascular disease (ASCVD) plans to recognize the importance of Lp(a) testing.
Background And Aims:
Elevated concentrations of Lipoprotein (a) [Lp(a)] is an inherited, causal risk factor for atherosclerotic cardiovascular disease (ASCVD). This study aims to investigate the clinical utility for patients, and the economic benefit to healthcare systems and society of measuring Lp(a) concentrations more widely today.
Methods:
We conducted a structured literature review to identify the economic and health benefits and costs of measuring the Lp(a) concentration, potential barriers hindering the uptake of the measure, and potential solutions to address them. These findings were then discussed in an advisory board attended by experts and patient organisations.
Results:
It was found that if Lp(a) concentration is measured more widely today, patients, healthcare system and society would experience clinical and economic benefits even before specific Lp(a) lowering pharmacological treatments become available. Furthermore, a wider uptake of the Lp(a) measurement would support the development of epidemiological data.
Conclusions:
For Lp(a) measurement to be more widely used, key barriers which are hindering its uptake need to be addressed. These include i) the perception that the measure may have limited clinical value, ii) lack of awareness on Lp(a), iii) lack of data on the CV benefit of reducing Lp(a), iv) technical and clinical guidelines barriers, and v) healthcare system barriers. Scientific communities and industry should collaborate to address technical challenges and deficiencies in clinical guidelines. However, policy intervention will be crucial for national ASCVD plans to acknowledge the importance of Lp(a).
More Related Videos
07:29Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
06:16Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease
Published on: August 9, 2024
Related Concept Videos
Coronary Artery Disease IV: Preventive Measures
Atherosclerosis III: Management
Coronary Artery Disease I: Introduction
Atherosclerosis IV: Nursing Management
Lifestyle Factors and Health
Benefits of Physical Activity
Physical activity, whether through structured exercise or casual activities like walking, biking, or dancing, is a cornerstone of a...
Pre-Procedural Guidelines for Assessing Blood Pressure